Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
-
Jasplakinolide (HB3946)
Description:Cell permeable, non-fluorescent F-actin probe. Induces actin polymerization and stabilization.
Purity:>98%
-
-
LY 294002 hydrochloride (HB2266)
Description:PI3-K inhibitor. Suppresses mESC proliferation.
Purity:>99%
-
Methylene Blue (HB0409)
Description:Biological dye, redox indicator and soluble guanylyl cyclase inhibitor
-
Minocycline hydrochloride (HB4617)
Description:Broad spectrum antibiotic. Potent microglial activation inhibitor. Allows formation of EPSs.
Purity:>98%
-
Nocodazole (HB3999)
Description:Mitosis inhibitor, widely used as a cell cycle synchronizing agent. Enhances HDR efficiency and increases Cas9-mediated gene editing frequencies.
Purity:>98%
